Table 3.
Ongoing clinical trials investigating viral vaccines in cancer.
| Clinical Trial Identifier Code | Investigation Plan | Viral vaccine/ Drug | Clinical Setting Line | Primary Endpoint | Stage of Development | Clinical Trials Status |
|---|---|---|---|---|---|---|
| NCT04745377 | 300 participants, Observational, Case-Control |
SARS-COV-2 | First line | Rate of Covid19 Infection post vaccination | Case-Control | Recruiting |
| NCT04410874 | 45 participants, Sequential Assignment, Open Label |
Imvamune | First line | MTD | 2 | Recruiting |
| NCT03315975 | 40 participants, Interventional, Single group Assignment, Open Label |
Inactivated influenza vaccine | First line | Neutralizing antibody response | 4 | Active, not recruiting |
| NCT04521764 | 33 participants, Interventional, Single group Assignment, Open Label |
modified measles virus (MV-s-NAP) | Second line or later line | MTD | 1 | Recruiting |
| NCT03848039 | 1220 participants, Interventional, Randomized Assignment, Open Label |
Gardasil-9 | First line | Evaluation of DRR | 3 | Not yet recruiting |
| NCT01376505 | 100 participants, Non-Randomized, Parallel Assignment, Open Label |
HER-2 vaccine | First line | Safety and duration of immune response | 1 | Recruiting |
| NCT04410900 | 41 participants, Non-Randomized, Parallel Assignment, Open Label |
Wistar Rabies Virus | First line | Positive vaccine response | 1 | Recruiting |
| NCT03113487 | 28 participants, Interventional, Single group Assignment, Open Label |
Vaccinia Virus expressing p53, Pembrolizumab | Second line or later line | PFS | 2 | Recruiting |
| NCT02432963 | 19 participants, Interventional, Single group Assignment, Open Label |
Vaccinia Virus expressing p53, Pembrolizumab | First line | Tolerability | 1 | Active, not recruiting |
| NCT02285816 | 56 participants, Non-Randomized, Parallel Assignment, Open Label |
MG1MA3 AdMA3 |
Second line or later line | MFD | 2 | Active, not recruiting |
| NCT03439085 | 77 participants, Interventional, Single Group Assignment, Open Label |
IL-12 DNA plasmids, MEDI0457, Durvalumab | First line | ORR | 2 | Active, not recruiting |
| NCT04836793 | 300 participants, observational, Cohort |
Additional biological samples | First line | IgG levels after Covid19 vaccination | Recruiting | |
| NCT02700230 | 30 participants, Interventional, Single Group Assignment, Open Label |
Measles Virus Encoding Thyroidal Sodium Iodide Symporter | First line | Dose Response | 1 | Recruiting |
| NCT02865135 | 11 participants, Interventional, Single Group Assignment, Open Label |
DPX-E7 vaccine | First line | SAE | 2 | Active, not recruiting |
| NCT04355806 | 160 participants, Observational, Prospective Assignment, |
PD-1/PD-L1 inhibitors, Inactivated trivalent influenza vaccine | First line | IgG levels | Not yet recruiting | |
| NCT04667702 | 330 participants, Observational, Prospective Assignment, |
HPV | First line | Vaccine Hesitancy | Recruiting | |
| NCT04774887 | 1200 participants, Interventional, Single group Assignment, Open Label |
HPV | First line | Risk to HPV | Not Applicable | Not yet recruiting |
| NCT00092534 | 12,167 participants, Interventional, Randomized, Single Group Assignment, Double Masking |
Gardasil, HPV | First line | Incidence of Endpoint of HPV | 3 | Active, not recruiting |
| NCT02977156 | 22 participants, Interventional, Single group Assignment, Open Label |
Pexa-Vec, Ipilimumab | First line | DLTs, ORR | 1 | Active, not recruiting |
| NCT03618953 | 75 participants, Non-Randomized, Parallel Assignment, Open Label |
Ad-E6E7 MG1-E6E7 Atezolizumab |
First line | Safety | 1 | Active, not recruiting |
| NCT03560752 | 36 participants, Interventional, Single Group Assignment, Open Label |
CMV-Modified Vaccinia Ankara Vaccine | First line | Safety | 2 | Recruiting |
| NCT02653118 | 4453 participants, Observational, Cohort, Open Label |
V503, GARDASIL | First line | Incidence of HPV | Active, not recruiting | |
| NCT04847050 | 220 participants, Non-Randomized, Parallel Assignment, Open Label |
mRNA-1273 | First line | Safety | 2 | Recruiting |
| NCT04854980 | 55 participants, Observational, Prospective Assignment, |
Blood | First line | Immune response to vaccine | Recruiting | |
| NCT04580771 | 35 participants, Interventional, Single Group Assignment, Open label |
Cisplatin Liposomal HPV-16 E6/E7 Multi-peptide Vaccine PDS0101 |
First line | Rate of grade | 2 | Recruiting |
| NCT03547999 | 78 participants, Parallel Assignment, Interventional, Randomized, Open Label | mFOLFOX6, MVA-BN-CV301, FPV-CV301, Nivolumab | First line | OS | 2 | Active, not recruiting |
| NCT02415387 | 180 participants, Crossover Assignment, Interventional, Randomized, Quadruple | typhoid vaccine | First line | Change in IL6 levels | Not Applicable | Recruiting |
| NCT04935528 | 430 participants, Single group Assignment, Interventional, Randomized, Open Label | ELISPOT, Serology | First line | seroprevalence of SARS-CoV-2 | Not Applicable | Recruiting |
| NCT05237947 | 5000 participants, Parallel Assignment, Interventional, Randomized, Double | DTP, Questionnaire, HPV | First line | Incidence of persistent HPV infection | 4 | Enrolling by invitation |
| NCT02649439 | 97 participants, Parallel Assignment, Interventional, Randomized, Open Label | PROSTVAC –V, PROSTVAC-F | First line | Tumor growth rate | 2 |
Active, not recruiting |
| NCT01867333 | 57 participants, Parallel Assignment, Interventional, Randomized, Open Label | PROSTVAC-F/TRICOM PROSTVAC-V/TRICOM, Enzalutamide (Xtandi) |
First line | Increase in time to progression | 2 | Active, not recruiting |
| NCT05078866 | 45 participants, Single group Assignment, Interventional, Randomized, Open Label | GAd-209-FSP, MVA-209-FSP | First line | Adverse events | 2 | Not yet recruiting |
| NCT04041310 | 84 participants, Sequential Assignment, Interventional, Non-Randomized | GAd-209-FSP, MVA-209-FSP | First line | Toxicity | 2 | Recruiting |
| NCT04977024 | 240 participants, Parallel Assignment, Interventional, Triple masking | COVID-19 Vaccine | First line | biological activity | 2 | Recruiting |
| NCT02002182 | 15 participants, Non-randomized Parallel Assignment, Interventional, Open Label | ADXS11-001 (ADXS-HPV) | First line | HPV-Specific T Cell Response Rate | 2 | Active, not recruiting |
| NCT04442048 | 195 participants, Randomized Parallel Assignment, Interventional, Open Label | IMM-101 | First line | rate of “flu-like illness” | 3 | Active, not recruiting |
| NCT03603808 | 80 participants, Single group Assignment, Interventional, Randomized, Open Label | HPV DNA Plasmids (VGX-3100) | First line | ORR | 2 | Recruiting |
| NCT05173324 | 8000 participants, Randomized, Parallel Assignment, Quadruple |
HPV vaccine HAV vaccine | First line | HPV prevalent infections | 3 | Not yet recruiting |
| NCT03350698 | 100 participants, Randomized, Single group Assignment, Open label |
Gardasil-9 | First line | Prevention | 4 | Recruiting |
| NCT04635423 | 1050 participants, Randomized, Parallel Assignment, Triple |
V503 | First line | Combined incidence of HPV 6/11/16/18-related anogenital persistent infection | 3 | Active, not recruiting |
| NCT04274153 | 130 participants, Single group Assignment, Interventional, Open label |
Gardasil9 | First line | Immunogenicity of HPV vaccine | 4 | Recruiting |
| NCT02834637 | 930 participants, Parallel Assignment, Interventional, Randomized, Open Label | bivalent HPV vaccine, nonavalent HPV vaccine | First line | Proportion with HPV 16/18-specific seropositivity | 3 | Active, not recruiting |
| NCT03284866 | 536 participants, Parallel Assignment, Interventional, Randomized, Double | Gardasil 9 | First line | Occurrence of cervical cancer | 3 | Recruiting |
| NCT02649855 | 74 participants, Parallel Assignment, Interventional, Randomized, Open Label | PROSTVAC-V, PROSTVAC-F, Docetaxel | First line | Response/efficacy | 2 | Active, not recruiting |
| NCT03315871 | 34 participants, Parallel Assignment, Interventional, Non-Randomized, Open Label | PROSTVAC-V, PROSTVAC-F, MSB0011359C | First line | Response of combination immunotherapy | 2 | Recruiting |
| NCT02396134 | 133 participants, Parallel Assignment, Interventional, Non-Randomized, Triple masking | CMVpp65-A*0201 peptide vaccine | First line | non-relapse mortality | 2 | Active, not recruiting |
| NCT05266898 | 150 participants, Single group Assignment, Interventional, Open Label | Human papillomavirus 9-valent vaccine | First line | change in serological response to Gardasil-9 | 4 | Not yet recruiting |
| NCT01824537 | 1000 participants, Randomized, Factorial Assignment, Interventional, Quadruple | Gardasil 9, Hepatitis A vaccine | First line | Reduction in HPV type concordance | 4 | Recruiting |
| NCT04534205 | 285 participants, Randomized, Parallel Assignment, Interventional, Open Label | BNT113, Pembrolizumab | First line | TEAE and ORR | 2 | Recruiting |
| NCT04060277 | 128 participants, Randomized, Parallel Assignment, Interventional, Open Label | Letermovir, Multi-peptide CMV-Modified Vaccinia Ankara Vaccine | First line | Non-relapse mortality | 2 | Recruiting |
| NCT03702231 | 116 participants, Non-Randomized, Parallel Assignment, Interventional, Open Label | Zoster Vaccine Recombinant, Adjuvanted | First line | Safety and Tolerability | 2 | Active, not recruiting |
| NCT04484532 | 200 participants, Single group Assignment, Interventional, Open Label | Trivalent Influenza Vaccine | Second or later line | Antibody response | 4 | Recruiting |
| NCT03180034 | 25,000 participants, Randomized, Parallel Assignment, Interventional, Double | DTP adsorbed, HPV bivalent, HPV Nonavalent | Second or later line | Incidence of persistent human papillomavirus (HPV)-16 or 18 cervical infections | 4 | Active, not recruiting |
| NCT00834093 | 18 participants, Single group Assignment, Interventional, Open Label | Epstein-Barr Virus Specific Immunotherapy | First line | ORR | 2 | Active, not recruiting |
| NCT03728881 | 1240 participants, Non-Randomized, Parallel Assignment, Interventional, Open Label | Quadrivalent HPV virus, bivalent HPV vaccine | First line | Antibody levels of HPV16 | 3 | Active, not recruiting |
| NCT02506933 | 102 participants, Randomized, Parallel Assignment, Double masking | Multi-peptide CMV-Modified Vaccinia Ankara Vaccine | First line | CMV events encompassing any CMV reactivation | 2 | Active, not recruiting |
| NCT04046445 | 96 participants, Non-Randomized, Parallel Assignment, Interventional, Open Label | ATP128, BI 754091, VSV-GP128 | First line | safety and tolerability and SAEs | 2 | Recruiting |
| NCT02481414 | 125 participants, Randomized, Parallel Assignment, Interventional, Open Label | PepCan, Candin | Second or later line | Efficacy | 2 | Active, not recruiting |
| NCT03391921 | 170 participants, Randomized, Parallel Assignment, Interventional, Open Label | Vaccine | Second or later line | Rate of seroconversion in HPV antibodies against HPV | 4 | Active, not recruiting |
| NCT05262010 | 13,500 participants, Randomized, Parallel Assignment, Interventional, Open Label | 11-valent recombinant human papilloma virus vaccine | First line | Person-years incidence of CIN2 + associated with HPV6/11/16/18 | 3 | Not yet recruiting |
| NCT04436133 | 480 participants, Randomized, Parallel Assignment, Interventional, Double | 11-valent recombinant human papilloma virus vaccine, Gardasil 9 | First line | Anti-HPV neutralizing antibodies GMT | 2 | Active, not recruiting |
| NCT03943875 | 512 participants, Randomized, Parallel Assignment, Interventional, Open Label | 9-valent HPV vaccine | First line | Efficacy | 4 | Recruiting |
| NCT04482933 | 30 participants, single group Assignment, Interventional, Open Label | Biological G207 | Second line or later line | Efficacy | 2 | Not yet recruiting |
| NCT04199689 | 6000 participants, Randomized, Parallel Assignment, Interventional, Triple masking | 9vHPV Vaccine | Second line or later line | Incidence of HPV | 3 | Active, not recruiting |
| NCT03903562 | 1990 participants, Randomized, Single group Assignment, Interventional, Open Label | V503 | First line | Serum antibody titers for HPV | 3 | Active, not recruiting |
| NCT04953130 | 10,400 participants, Randomized, Parallel Assignment, Interventional, Open Label | Gardasil HPV vaccine | First line | Impact of HPV vaccination | 4 | Not yet recruiting |
| NCT04951323 | anti-COVID19 mRNA-based vaccine | anti-COVID19 mRNA-based vaccine (BNT162b2) | First line | Quantification of anti-SARS-CoV-2 receptor binding domain specific IgG | 3 | Recruiting |
| NCT02750202 | 75 participants, Randomized, Parallel Assignment, Interventional, single masking | Quadrivalent HPV vaccine, Hepatitis B vaccine | First line | Change in the genital wart lesion | 3 | Recruiting |
| NCT05291845 | 75 participants, Randomized, Factorial Assignment, Interventional, open label | Candida antigen vaccine, Bivalent HPV vaccine | Second line or later line | complete response | 2 | Not yet recruiting |
| NCT05027776 | 1348 participants, Randomized, Parallel Assignment, Interventional, open label | HPV vaccine | First line | Primary immunogenicity | 3 | Recruiting |
| NCT04708041 | 700 participants, Randomized, Parallel Assignment, Interventional, open label | 9vHPV vaccine | First line | GMT of HPV | 3 | Active, not recruiting |
| NCT04474821 | 300 participants, Randomized, Single group Assignment, Interventional, open label | Human Papillomavirus Infection | Second line or later line | Acceptance and completion rates of free HPV vaccination | 4 | Recruiting |
| NCT04895020 | 1200 participants, Single group Assignment, Interventional, open label | 9-valent HPV vaccine | First line | primary immunogenicity | 3 | Recruiting |
| NCT04422366 | 8000 participants, Parallel group Assignment, Interventional, open label | 9-valent Human Papillomavirus, GARDASIL | First line | person-year incidence of HPV | 3 | Recruiting |
| NCT03998254 | 6000 participants, Parallel group Assignment, Interventional, double label | V503, Gardasil | Second line or later line | Combined Incidence of HPV related 12-month Persistent Infection | 3 | Active, not recruiting |
| NCT05285826 | 8100 participants, Parallel group Assignment, Interventional, double label | 9vHPV vaccine | First line | Combined Incidence of HPV 58-related External Genital and Intra-anal 12-month Persistent Infection | 3 | Recruiting |
| NCT05279248 | 300 participants, Parallel Assignment, Interventional, Open label | HPV + MMR,HPV | First line | GMT of anti-HPV 16 and 18 at 7 months | 4 | Active, not recruiting |
| NCT04870333 | 5000 participants, Parallel Assignment, Randomized, Interventional, Open label |
Niclosamide, Ciclesonide, Sotrovimab | First line | Prevention | 3 | Recruiting |
| NCT05119855 | 400 participants, Parallel Assignment, Randomized, Interventional, Open label |
9vHPV Vaccine, mRNA-1273 Vaccine | First line | GMT of HPV | 3 | Recruiting |